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Abstract
The HIV-1 gp41 envelope (Env) membrane proximal external region (MPER) is an important vaccine target that in rare
subjects can elicit neutralizing antibodies. One mechanism proposed for rarity of MPER neutralizing antibody generation is
lack of reverted unmutated ancestor (putative naive B cell receptor) antibody reactivity with HIV-1 envelope. We have
studied the effect of partial deglycosylation under non-denaturing (native) conditions on gp140 Env antigenicity for MPER
neutralizing antibodies and their reverted unmutated ancestor antibodies. We found that native deglycosylation of clade B
JRFL gp140 as well as group M consensus gp140 Env CON-S selectively increased the reactivity of Env with the broad
neutralizing human mAbs, 2F5 and 4E10. Whereas fully glycosylated gp140 Env either did not bind (JRFL), or weakly bound
(CON-S), 2F5 and 4E10 reverted unmutated ancestors, natively deglycosylated JRFL and CON-S gp140 Envs did bind well to
these putative mimics of naive B cell receptors. These data predict that partially deglycoslated Env would bind better than
fully glycosylated Env to gp41-specific naı̈ve B cells with improved immunogenicity. In this regard, immunization of rhesus
macaques demonstrated enhanced immunogenicity of the 2F5 MPER epitope on deglyosylated JRFL gp140 compared to
glycosylated JRFL gp140. Thus, the lack of 2F5 and 4E10 reverted unmutated ancestor binding to gp140 Env may not always
be due to lack of unmutated ancestor antibody reactivity with gp41 peptide epitopes, but rather, may be due to glycan
interference of binding of unmutated ancestor antibodies of broad neutralizing mAb to Env gp41.
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Introduction
Two rare human monoclonal antibodes (mAbs), 2F5 and 4E10,
bind to linear epitopes in the gp160 membrane proximal external
region (MPER) [1,2]. The core sequence of 2F5 epitope is aa 662–
668 (ELDKWAS), and that of 4E10 is aa 671–676 NWFDIT [3].
The crystal structures of the 2F5 and 4E10 Fabs in complex with
peptides containing their gp41 core epitopes demonstrated that
only a relatively small portion of the CDRH3 antibody regions
bound the MPER [4,5]. Both mAbs 2F5 and 4E10 are
polyreactive for lipids and have long hydrophobic heavy chain
complementarity determining regions (HCDR3s) [6]. Hydropho-
bic HCDR3 loops of the variable region of the heavy chain (VH)
of both mAbs 2F5 and 4E10 bind viron lipids in a two-step
conformational change model that is required for antibody
neutralization [7–11]. Thus, mAbs 2F5 and 4E10 use their
autoreactive specificities to mediate anti-HIV-1 activity [8,12].
The autoreactivity of mAbs 2F5 and 4E10 has raised the
hypothesis that their rarity is due to tolerance control due to their
polyreactivity with host antigens [6]. Indeed, the creation of
knock-in mice with 2F5 [13] and 4E10 [14] VHs have
demonstrated this to be the case in these mice. MAbs 2F5 and
4E10 rarely bind well to gp140 oligomers, possibly in part due to
lack of formation of the gp41 intermediate form that binds to
mAbs 2F5 and 4E10 [15]. Xiao et al. [16] have suggested that an
additional reason for the rarity of broadly neutralizing antibodies
in general, and 2F5-like antibodies in particular, is the lack of
reactivity of HIV-1 Env with the unmutated ancestors of broad
neutralizing antibodies. That is, this hypothesis states that there
are ‘‘holes’’ in the naı̈ve B cell repertoire resulting in lack of
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unmutated antibodies that can bind and respond to conserved Env
broadly neutralizing epitopes.
Glycosylation can modulate the binding of antibodies to gp120
with gain or loss of a glycosylation site in a virus mutant affecting
both Env antigenicity and virus neutralization sensitivity [17–23].
Analysis of HIV-1 Env mutated by site-directed mutagenesis has
indicated that Env glycans in the first and second variable (V1/V2)
loops [24], the third (V3) [25] and fourth variable (V4) loops of
gp120 [26] modulate the binding of antibodies to Env. Yuste et al.
demonstrated that glycosylation site deletion mutants of SIV-
mac239 induced neutralizing antibodies to a novel conserved
region C-terminal to the gp41 immunodominant region [23]. In
addition, two recent studies have demonstrated that the N-linked
glycosylation site at Env aa 413 is associated with induction of
broad neutralizing antibodies [27,28].
In this study, we have partially deglycosylated JRFL gp140 and
group M consensus gp140 (CON-S) [29] Env proteins under
native, non-denaturing conditions, and demonstrated enhanced
binding of mAbs 4E10 and 2F5 to deglycosylated Env. While the
reverted unmutated ancestor antibodies of 2F5 and 4E10 were
either non-reactive (with glycosylated JRFL Env), or poorly
reactive (with glycosylated CON-S Env), they reacted well with
partially deglycosylated gp140 HIV-1 envelope, indicating for
some HIV-1 envelopes, an intact naı̈ve B cell repertoire for 2F5
and 4E10 gp41 neutralizing epitopes.
Results
Analysis of Deglycosylated HIV-1 gp140 Env Proteins in
SDS-PAGE, Western Blot Analysis and ELISA
To deglycosylate maximally HIV-1 Env under non-denaturing
conditions, while in order to maintaining the native conforma-
tions, HIV-1 JRFL recombinant gp140 Env was treated with a
wide dose range of PNGase F. Figure 1 shows JRFL gp140 Env
protein treated with progressive deglycosylation (PNGase F 5, 10,
20, 50, 100 and 500 U per mg of Env protein) analyzed in SDS-
PAGE and Western blots. After deglycosylation, the molecular
Author Summary
Critical to the design of an effective HIV-1 vaccine that will
induce long-lasting broadly neutralizing antibodies is to
understand why broad neutralizing antibodies are not
induced. One hypothesis is that there are ‘‘holes’’ in the
naı̈ve B cell repertoires for unmutated B cell receptors that
can bind to HIV-1 envelope (Env) neutralizing epitopes. In
this paper, we test this hypothesis for the rare HIV-1
envelope gp41 broad neutralizing monoclonal antibodes
(mAbs), called 2F5 and 4E10, and show that indeed, fully
glycosylated Env does not bind to inferred unmutated
ancestor antibodies (mimics of naı̈ve B cell receptors) of
mAbs 2F5 and 4E10, but that partially deglycosylated Envs
that have had glycans removed under non-denaturing
conditions, did bind to 2F5 and 4E10 unmutated ancestor
antibodies. Thus, rather than there being a lack of
existence of germline B cell receptors for gp41 broad
neutralizing antibodies, one impediment to induction of
gp41 broad neutralizing antibodies may be glycan
interference with unmutated antibody binding to gp41
envelope.
Figure 1. Analysis of deglycosylated JRFL protein in reducing SDS-PAGE and Western-blotting with a panel of HIV-1 MAbs. WT
glycosylated and deglycosylated JRFL gp140 Env proteins were fractionated in 4–12% SDS-PAGE under reducing conditions, stained with
coommassie blue or were transferred to nitrocelose membranes and blotted with a panel of human anti-HIV-1 mAbs as indicated. WT glycosylated
JRFL gp140 Env protein is labeleled as [-] on the top of the lane. The amount of PNGase F (in U) used in the reaction per mg of protein is indicated on
the top of lanes with progressively deglycosylation. Lane * refers to treatment of denatured JRFL gp140 protein with PNGaseF (500 U) at 37 degrees
for 2 hours. Progressive reductions in molecular weight of JRFL gp140 with increasing amounts of PNGase used to deglycosylate JRFL gp140 Env are
shown in Coomassie staining gels and Western blots using mAbs F39, 2F5 and 4E10. The higher molecular weight band(s) shown in lane * in the
coomassie stained gel and in Western blots by F39, 2F5 and 2G12 were due to the incomplete reduction of JRFL gp140 Env protein (see coomassie
stained gel in Figure S1).
doi:10.1371/journal.ppat.1002200.g001
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mass of HIV-1 JRFL gp140 Env protein was progressively reduced
with increasing doses of PNGase F, with maximal deglycosylation
under non-denaturing conditions using 500 U PNGase F per 1 mg
of Env. At this dose, JRFL Env gp140 molecular mass was reduced
to near that of Env treated with PNGase F under denaturing
conditions (approximately 80 kDa Env shown in lanes with an
asterisk in Figure 1). In blue BN-PAGE gel, analysis, JRFL gp140
Env deglycosylated under native conditions using 500U/ug Env
PNGase F migrated as monomers, dimers and trimers in the same
manner as did wild-type (WT) glycosylated JRFL Env gp140
(Figure S1A).
In SDS-PAGE and Western blot analysis under reducing
conditions, there was weak or no binding of deglycosylated JRFL
Env gp140 to the co-receptor binding site mAb 17b [30], to the
CD4 binding site mAb 1b12 [20], or to the gp120 conformational-
dependent mAb, A32 [31] (Figure 1). However, the binding of
anti-V3 loop mAb F39F [31] to JRFL gp140 was not affected by
deglycosylation when assayed under these conditions (Figure 1). In
contrast, the binding of anti-carbohydrate mAb 2G12 to
deglycosylated JRFL gp140 was decreased with progressive native
deglycosylation. The binding of gp41 MPER human mAb 2F5
was not inhibited by deglycosylation or reduction, while
progressive deglycosylation appeared to increase binding of the
gp41 MPER antibody 4E10 to HIV-1 JRFL gp140 protein.
Maximal binding of mAb 4E10 to JRFL Env protein was seen by
using the deglycosylated Env treated with the highest level of
PNGase F (500 U per mg of Env). This enhanced level of 4E10
binding was similar to the level of 4E10 binding to fully PNGase F-
deglycosylated Env under denaturing conditions (asterisk,
Figure 1).
To compare antigenic and functional epitopes, glycosylated and
natively deglycosylated JRFL Envs were assayed for their ability to
bind sCD4, and for their ability to undergo CD4 and mAb A32
induction of the CCR5 binding site as defined by binding of mAb
17b to Env. Thus, sCD4, mAb A32, or gp120 C1 control mAb T8
was immobilized on a surface plasmon reasonance (SPR) sensor
chip and then either WT glycosylated or deglycosylated JRFL
gp140 were flowed over the chip, followed by flowing over mAb
17b (Figures 2A, 2B). First, we found that WT glycosylated JRFL
gp140 Env bound to sCD4 with Kd of 5.7 nM, while
deglycosylated JRFL gp140 protein bound sCD4 with Kd of
35.3 nM (Figure 2A). The WT glycosylated JRFL gp140 Env was
induced to bind mAb17b following binding to either sCD4 or
mAb A32 with Kd of 9.5 nM and 6.0 nM, respectively, while the
deglycosylated JRFL gp140 Env was induced to bind mAb17b
following binding to either sCD4 or MAb A32 with slightly higher
Kd of 25.0 nM and 7.5 nM, respectively. No binding of mAb 17b
binding was observed following the binding of either WT
glycosylated or native deglycosylated Env to gp120 C1 mAb T8
(Figure 2B). Thus, native deglycosylation of JRFL gp140 Env did
not perturb the ability of the Env to undergo sCD4 and mAb A32-
induced exposure of the CCR5 Env binding site.
Increased Affinity of 4E10 and 2F5 mAbs for
Deglycosylated Env
To ask if indeed, the deglycosylation of JRFL oligomer induced
exposure of the MPER as suggested by reduced SDS-PAGE
Western blot analysis, we performed indirect ELISAs using serially
diluted human mAbs and a fixed amount of Env proteins captured
on ELISA plates by anti-gp120 C1 mouse mAb 3B3 [32]. In this
assay, both mAbs 2F5 and 4E10 bound glycosylated JRFL Env
protein with the apparent Kd of approximately 67 nM and
33 nM, respectively, while both mAbs 2F5 and 4E10 bound
significantly better to the natively deglycosylated JRFL Env with
apparent Kds of 4.9 nM and 6.1 nM, respectively (Figure 3). The
apparent Kds of mAbs 2F5 and 4E10 binding to natively
deglycosylated JRFL Env proteins treated with either 500 U, 20
U or 5 U per mg Env were all similar with apparent Kds of
3.7 nM, 4.9 nM and 4.5 nM for mAb 2F5, and 4.4 nM, 5.1 nM
and 6.1 nM for mAb 4E10 at these PNGase F concentrations,
respectively (Figure 3).
We next performed SPR analysis of binding of mAbs 2F5 and
4E10 to WT glycosylated and deglycosylated JRFL Env proteins
by flowing either glycosylated or deglycosylated JRFL Env
proteins over mAbs 4E10 or 2F5 captured on an SPR sensor
chip (Figure 4). Marked enhancement of mAb 4E10 binding to
deglycosylated JRFL Env (Figure 4A) was observed compared to
the binding of mAb 4E10 to the WT glycosylated JRFL
(Figure 4B). SPR analysis demonstrated that the enhancement of
4E10 binding to deglycosylated JRFL proteins was due to both a
faster on- rate (Kon) and a slower off rate (Koff) that resulted in a
net 15-fold decrease in the overall dissociation constant (Kd) of
4E10 binding from 154 nM for glycosylated JRFL Env to 10 nM
for native deglycosylated JRFL Env (Figures 4B and 4A). Similar
but weaker enhancement (6-fold) of 2F5 mAb binding to
deglycosylated JRFL Env was seen in SPR analysis (Kd = 38 nM
for 2F5 binding to deglycosylated Env vs. Kd = 212 nM of 2F5
binding to WT glycosylated Env) (Figures 4C and 4D).
Preserved DC-SIGN Binding By Natively Deglycosylated
JRFL Env
We next evaluated the binding of natively partially deglycosy-
lated Env to DC-SIGN using AF647-labeled JRFL Env. We found
that neither partial deglycosylation nor labeling of AF647 had any
effect on the binding of JRFL gp140 Env protein to CD4
expressing TZM-b1 cells (not shown). Natively deglycosylated
JRFL gp140 Env (treated with 500 U PNGase F per mg of Env)
retained the ability to bind to DC-SIGN-transfected 3T3 cells but
not control 3T3 cells (Figure 5) indicating preserved high mannose
residues on the PNGase-treated natively partially deglycosylated
Env.
The 2G12 Epitope was Maintained on JRFL Env After
Deglycosylation Under Native Conditions
It has previously been reported that binding of mAb 2G12
requires gp120 Env N-linked glycan at positions N286, N323, and
N330 [33]. Since native deglycosylation with PNGase F is not
complete, and the maximally deglycosylated JRFL gp140 Env
(treated with 500 U PNGase F per mg of Env) bound to DC-SIGN
transfected 293T cells, we asked if 500 U PNGase F-deglycosy-
lated gp140 could also bind the anti-gp120 carbohydrate-
dependent mAb 2G12.
Although the binding of 2G12 to deglycosylated JRFL protein
was weak in reducing SDS-PAGE Western blot analysis (Figure 1),
in SPR analysis in which Env is flowed over captured mAb,
binding of 2G12 to JRFL gp140 protein was maintained when
Env was treated with PNGase F (Figure 6). While 5U and 20U of
PNGase F did not decrease mAb 2G12 binding, 500U of PNGase
F treatment did decrease, but did not completely abrogate, mAb
2G12 binding (Figure 6).
Characterization of Env Carbohydrates Remaining on
JRFL gp140 After Deglycosylation Under Non-denaturing
Conditions
PNGase F 500 U-treated JRFL gp140 was subjected to
enzymatic digestion and LC-MS/MS analysis to define sites and
forms of glycan remaining on optimally deglycosylated gp140 (500
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U PNGase F) [34,35]. JRFL gp140 has 27 potential N-linked
glycosylation sites, and the occupied sites are composed of high
mannose, hybrid, and complex glycans [34,35]. The remaining
glycosylation on these sites was identified using a combination of
high resolution MS and MS/MS data of the endoglycosidase-
treated glycopeptides, as described in the section od Materials and
Methods. The resulting MS data is summarized in Supplemental
Table 1. Each peptide containing a potential glycosylation site was
detected as either a glycopeptide, a deglycosylated peptide, or as a
natively nonglycosylated speices.
Based on the amino acid sequence of JRFL gp140 (including the
signal peptide), all but four of the sites in the untreated protein
were fully or partially occupied with glycans (Figure 7 and Table
S1) (34). The unoccupied sites were: N141, N188, N611and N637.
Upon extensive deglycosylation (500 U PNGase F per 1 mg of
protein), the glycans at 12 out of 23 sites were removed: N88 (C1),
N135 (V1/V2), N138 (V1/V2), N156 (V1/V2), N160 (V1/V2),
N187 (V1/V2), N262 (C2), N276 (C2), N356 (C3) N462 (C4),
N616, and N625 (Figure 7). The 10 sites on which glycosylation
still remained were fractionally populated with glycans. Thus,
PNGase F cleaved a fraction of the glycans at these sites, but the
reaction was incomplete. Most of the conserved glycans were of
the high mannose type and included those glycans involved in the
2G12 binding (N295, N332, N386) [33] (Figure 7). Figure 8 shows
a model of JRFL gp140 Env before PNGase-F treatment
(Figure 8A) and after PNGase-F treatment (Figure 8B) based on
the cryo-EM structure (white mesh) of Liu et al. [36] and specific-
site glycan analysis before PNGase-F treatment [34] and after
treatment (Figure 7). Red molecules indicate gp120 amino acids,
blue indicates gp120 glycans, white indicates 2G12 glycans [37],
and yellow indicates gp41 glycans. Figure 8 depicts the loss of
many complex glycans on gp120 and the loss of two gp41 glycans
after PGNase-F treatment.
Binding of mAbs 4E10 and 2F5 to gp140 Is to gp41 and
Not to gp120
To determine if there were ancillary binding sites located on
gp120, as previously suggested [38], binding of mAbs 4E10 and
2F5 to deglycosylated HIV-1 Env 89.6 gp120 was determined
using the same non-denaturing conditions as used for binding of
mAbs 2F5 or 4E10 mAb binding to deglycosylated JRFL gp140.
We found that while sCD4 bound well to HIV-1 89.6 Env gp120
deglycosylated with up to 20 U PNGase F treatment, no binding of
either mAbs 2F5 or 4E10 to gp120 was seen (Figure S2). Thus, the
enhanced binding of mAbs 4E10 and 2F5 to the deglycosylated
JRFL gp140 protein was indeed due to the binding to the gp41
component of gp140.
Next, we asked if absorption of 50 mg/ml of 4E10 by increasing
amounts of either deglycosylated JRFL gp140 or deglycosylated
HIV-1 Env 89.6 gp120 could absorb the 4E10 binding activity for
the P-4E10 nominal peptide epitope.
As shown in Figure S3, addition of dilutions of absorbing JRFL
Env gp140 protein to 50 mg/ml mAb 4E10 absorbed 4E10
binding activity to nominal 4E10 gp41 peptide, while addition of
Env 89.6 gp120 (both WT glycosylated and PNGase F 20 U-
treated) did not (Figure S3). Thus, the expressed epitope on JRFL
gp140 is located on gp41 and PNGase F-treated gp140 absorbed
4E10 binding activity to the normal gp41 4E10 epitope peptide.
MAb 4E10 binding was the most enhanced of MPER
antibodies to PNGase F-treated JRFL Env. To determine if the
4E10 neutralizing epitope was the target for 4E10 binding, we
next asked if the nominal 4E10 binding epitope peptide (P-4E10:
SLWNWFNITNWLWYIK) could absorb out the mAb 4E10
binding activity to deglycosylated JRFL gp140 (Figure S4). As
shown in Figure S4, increasing amounts of the 4E10 epitope
peptide absorbed the binding activity of 5 mg/ml mAbs 4E10 to
the deglycosylated JRFL gp140.
Analysis of Deglycosylated JRFL Env Binding to 2F5 and
4E10 Reverted Unmutated Ancestors (Putative B Cell
Receptors of Naı̈ve B Cells)
While the somatically mutated 4E10 and 2F5 mAbs bound
better to natively deglycosylated Env than to glycosylated Env, an
immunogen needs to trigger the unmutated germline B cell
receptors on the surface of naı̈ve B cells [39,40]. It has been
previously demonstrated that a 2F5 RUA did not bind to fully
glycosylated Env [16]. To assess Env binding to reverted
unmutated antibody ancestors of the mutated mAbs 4E10 and
2F5, we used the program SoDA-2 [41] and Phylip’s NAML [42]
to infer RUAs of mAbs 2F5 and 4E10 resulting in two inferred
RUAs of mAb 2F5 and one RUA of mAb 4E10 (Table S2 in
SOM). These RUAs were produced in 293T cells as whole IgG1
antibodies by transfection and tested for binding to HIV-1 JFRL
gp140 Env proteins. We found that indeed, the inferred RUAs of
mAbs 4E10 and 2F5 did not bind to glycosylated JRFL gp140
Env, as previously shown for the 2F5 RUA by Xiao et al. [16].
However, both 2F5 and 4E10 RUAs did bind to natively
deglycosylated JRFL gp140 Env oligomer (Figure 9). While the
binding of the 2F5 RUAs to fully glycosylated JRFL gp140 Env
was unmeasurable (Figures 9A and 19C), the binding Kds for
partially deglycosylated JRFL gp140 Env were 258 nM and
270 nM, respectively (Figures 9B and 9D). Similarly, the binding
of the 4E10 RUA for glycosylated Env was also unmeasurable
(Figure 9E), while the binding Kd of the 4E10 RUA for the
natively deglycosylated Env was 318 nM (Figure 9F). Thus, gp140
glycans mask or modulate the availability of MPER neutralizing
epitopes for 2F5 and 4E10 RUA binding to gp41 linear
neutralizing epitopes on the JRFL Env gp140 oligomers.
Demonstration that Native Partial Deglycosylation of
Another Env, the Group M Consensus Env, CON-S gp140,
also Exposes the MPER Region and Enhances Binding of
Deglycosylated Env to 2F5 and 4E10 RUAs
To determine if the effect of PNGase F on JRFL gp140 is
generalizable to other Envs, we studied the effect of partial native
deglycosylation on the group M consensus gp140 Env CON-S
[29]. This Env has previously been reported to induce a degree of
Figure 2. Analysis of antigenic epitopes expressed on WT glycosylated and deglycosylated JRFL gp140 by surface plasmon
resonance (SRP). SPR assays were performed as described in Materials and Methods. Shown are the ability of WT glycosylated and deglycosylated
JRFL gp140 to bind to sCD4 (Panel A) and to mAb 17B (Panel B). sCD4 or HIV-1 mAbs T8 and A32 were covalently immobilized to a CM5 sensor chip
(BIAcore), and WT glycosylated (10 to 75 mg/ml) and deglycosylated JRFL gp140 were injected over each surface (100 and 300 ug/ml, respectively). To
determine induction of 17b mAb binding to WT glycosylated and deglycosylated JRFL gp140, Env proteins were captured on individual flow cells
immobilized with sCD4 (80–120 response units or RU) or mAb A32 (,130–300RU) or T8 (,340–450 RU), with about the same RU of Env gp140
captured on each surface prior to injection of varying concentrations of 17 mAb. Following stabilization of each of the surfaces, mAb 17b (10–100 mg/
ml) was injected and flowed over each of the Env captured surfaces as illustrated in the diagram above the SPR profile in Panel B. Each analysis was
performed at least twice.
doi:10.1371/journal.ppat.1002200.g002
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breadth among clade A, B and C Tier 1 virus strains [29]. We
found that, like JRFL gp140 oligomers, PGNgase F 500 U
treatment under native conditions of CONS gp140 resulted in
reduced MW of monomers, dimers and trimers, and did not lead
to Env degradation (Figure S1). Second, native deglycosylation of
CON-S gp140 resulted in maintainance of sCD4 binding
(Kd = 7.4 nM for CON-S glycosylated Env and Kd = 9.4 nM for
deglycosylated Env) (Figure S5). Third, like deglycosylated JRFL
gp140, deglycosylated CON-S gp140 Env could undergo sCD4
and A32 mAb-induced 17b binding to the CCR5 co-receptor
gp120 binding site (Figure S6), and both mAbs 2F5 (Figures S7A
and S7B) and 4E10 (Figures S7C and S7D) bound with lower Kds
to deglycosylated CON-S gp140 when compared to WT
glycosylated CON-S gp140.
Interestingly, the WT glycosylated CON-S gp140 constitutively
bound (before deglycosylation) to both 2F5 RUAs 1 and 2 (Figures
S8A and S8C), demonstrating that some glycosylated recombinant
Envs do have the ability to bind to broadly neutralizing antibody
germline antibodies. 2F5 RUA1 bound better to glycosylated
CON-S gp140 than did 2F5 RUA2 (Kd = 118 nM for RUA1 vs
Kd = 4.0 mM for RUA2). The enhancement of binding to the
deglycosylated CON-S was only two-fold for RUA1 (Kd = 67 nM)
Figure 3. Binding kinetics of mAbs 2F5 and 4E10 to WT glycosylated and deglycosylated JRFL gp140. Binding of mAbs 2F5 and 4E10 to
WT glycosylated and progressively deglycosylated JRFL gp140 proteins was determined in direct ELISA. An anti-HIV-1 Env C1 region antibody 3B3
[31] was coated on the 96-well plates to capture glycosylated and progressively deglycosylated JRFL gp140 proteins following by incubation with
mAbs 2F5 and 4E10. The mAbs 2F5 and 4E10 were assayed at the concentrations as indicated on the x-axis. Data presented are representative of 3
independent experiments.
doi:10.1371/journal.ppat.1002200.g003
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while the enhancement of binding of 2F5 RUA2 for deglycosy-
lated CON-S gp140 Env was an order of magnitude (Kd = 4.0 mM
for WT glycosylated CON-S gp140 and Kd = 0.36 mM for
deglycosylated CON-S Env).
For CON-S gp140, the pattern of binding to the 4E10 RUA was
similar to that of JRFL gp140, with no measurable binding of
glycosylated CON-S gp140 to the 4E10 RUA, while the deglyco-
sylated CON-S gp140 bound to the 4E10 RUA with a Kd of
0.23 mM (Figures S8E and S8F). That WT glycosylated CON-S
gp140 binds to the RUAs of 2F5 in this setting is not surprising since
we have previously published that CON-S gp140 produced in 293T
cells (as the CON-S gp140 was produced in this study) is not
glycosylated in gp41 [34]. That the expression of the epitopes for both
mAbs 2F5 and 4E10 are further enhanced on deglycosylated CON-S
therefore suggests that removing glycans on gp120 can also affect
exposure of MPER neutralizing epitopes. Regardless, the effect of
PNGase F native deglycosylation is not unique to JRFL gp140 Env.
Immunogenicity of HIV-1 JRFL gp140 and Deglycosylated
JRFL gp140 Env Proteins in Rhesus Macaques
To determine if the enhanced binding of mAbs 4E10 and 2F5 and
their RUAs to deglycosylated HIV-1 JRFL gp140 Env might have
resulted in enhanced immunogenicity for induction of MPER
antibodies, 4 rhesus macaques per group were immunized with
either deglycosylated JRFL Env gp140 or WT JRFL gp140. Plasma
samples were obtained 2 weeks after the first priming and second
boosting immunizations and evaluated for binding antibody to the
immunizing Env and to 2F5 and 4E10 nominal membrane proximal
external region (MPER) peptides. Both the deglycosylated HIV-1
JRFL gp140 Env protein and WT JRFL gp140 Env were
immunogenic and induced similar levels of antibodies to the
immunizing Envs after 2 immunizations (Figure 10A). Whereas the
WT glycosylated JRFL gp140 Env induced minimal levels of
antibodies after the first and second immunizations to a 2F5 epitope
peptide (QQEKNEQELLELDKWASLWN), in contrast, the degly-
cosylated JRFL gp140 Env induced enhanced levels of 2F5 epitope
antibodies after the second immunization in 3 of 4 animals
(Figure 10B) (p = 0.035, Student’s t test). However, neither the
deglycosylated HIV-1 JRFL Env proteins nor WT JRFL gp140 Env
induced antibodies to HIV-1 MPER 4E10 epitope peptide,
SLWNWFNITNWLWYIK (data not shown). Finally, while anti-
bodies were present in both groups that neutralized the SF162.B
pseudovirus, neither group neutralized the 2F5-sensitive HIV-1 Env
BG1168.B pseudovirus (data not shown), indicating that the induced
rhesus MPER antibodies either were non-neutralizing or were of
insufficient titers to neutralize. Nonetheless, these data demonstrate
Figure 4. SPR assays for native and deglycosylated JRFL gp140 binding to mAbs 4E10 and 2F5. MAbs 4E10 (Panel A, B) and 2F5 (Panel C,
D) were bound to anti-human Ig Fc immobilized on the CM5 sensor chip. Varying concentrations (ranging from 5 to 100 ug/mL) of native (WT) and
deglycosylated (Deg) JRFL gp140 Envs were injected over the mAbs on the chip and binding kinetics were recorded. Rate constants and Kd
measurements were made using the 1:1 Langmuir model and data recorded are indicated in the individual panels. Deglycosylation of JRFL gp140
enhanced the Kd of 4E10 and 2F5 binding by ,15-fold and ,6-fold respectively. Data shown are representative of two experiments.
doi:10.1371/journal.ppat.1002200.g004
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proof-of-concept of enhanced 2F5 epitope immunogenicity of native
deglycosylated JRFL gp140 Env.
Discussion
We have demonstrated that non-denaturing (native) deglycosy-
lation of HIV-1 JRFL and the group M consensus gp140 envelope
oligomers with PNGase F resulted in enhanced Env binding to
gp41 broadly neutralizing mAbs 4E10 and 2F5, and as well,
induced or enhanced binding of gp140s to 2F5 and 4E10 reverted
unmutated ancestor antibodies. Moreover, immunization of the
JRFL deglycosylated gp140 Env resulted in enhanced antibody
induction to the gp41 2F5 peptide epitope.
Treatment of Env with glycosylation inhibitors and neuramin-
idase has been reported to enhance HIV-1 binding and
neutralization by mannose-binding lectin, and to facilitate
Figure 5. Binding of WT glycosylated and deglycosylated JRFL gp140 Env on DC-SIGN-expressing NIH 3T3 cells. The binding of
AF647-labeled WT glycosylated (histogram in red lines and deglycosylated JRFL Env gp140 (histograms in blue lines) to parent NIH 3T3 (histograms
shaded) and DC-SIGN-expressing NIH 3T3 cells (histograms not shaded) were analyzed by flow cytometry. Data shown are representative of three
experiments.
doi:10.1371/journal.ppat.1002200.g005
Figure 6. SPR assays for binding of native and deglycosylated JRFL gp140 to mAb 2G12. MAb 2G12 was immobilized on the CM5 chip.
The saturated amounts of native and representative deglycosylated proteins were then flown over the mAbs. The binding kinetics were recorded at
25uC. Deglycosylation of JRFLgp140 using lower dose of PGNase (20 U: mg) enhanced the binding of 2G12 but substantially decreased binding of
2G12. Data show binding curves of each deglycosylated and WT glycosylated protein injected at 50 mg/mL and 200 mg/mL respectively, and are
representative of two experiments.
doi:10.1371/journal.ppat.1002200.g006
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immunocapture of virions by both mAbs 2G12 and 2F5 [43].
Thus, the selective removal of complex glycans by non-denaturing
PNGase F treatment may similarly expose the 2F5 and 4E10
MPER binding site for enhanced mAbs 2F5 and 4E10 binding.
MAb 2G12 has been reported to bind to gp120 N-linked high
mannose residues at N295, N332, and N392, as well as with
peripheral glycans from 386 and 448 [3,37]. Interestingly, our
mass spectrometry analysis of deglycosylated JRFL gp140
demonstrated selective loss of N-linked glycans particularly around
V1 and V2 with high mannose residues at N295, N332, and N392
remaining intact [34,35]. The non-denatured deglycosylated JRFL
gp140 Env bound well to mAb 2G12 and also bound to DC-
SIGN. In this regard, the gp120 high mannose residues involved
in 2G12-gp120 binding have been reported to be involved in
gp120-DC-SIGN binding [44]. Thus, selective removal of gp140
glycans may induce conformational changes or unmasking of the
gp41 MPER 4E10 epitope that results in enhanced on-rate (ka) of
mAbs 4E10 and 2F5 binding.
Walker et al. have recently reported that 25% chronically
infected HIV-1 subjects with broad neutralizing antibodies had
neutralizing plasma antibody activity targeted at Env glycans at
N332, and at N295 in some subjects [45]. Although N332 and
N295 glycans are involved in mAb 2G12 binding, their N332
and/or N295 activity was found to bind a glycan epitope distinct
from that of 2G12 [45]. That PNGase treatment of HIV-1 Env
under non-denaturing condition retained all N-linked glycans
involved in 2G12 and in the novel N295/N332 neutralizing
epitopes, suggests natively deglycosylated HIV-1 gp120 or gp140
Env may be of use in vaccine formulations targeted at elicitation of
anti-glycan gp120 neutralizing antibodies.
Yuste et al., has demonstrated that mutations in gp41 N-linked
glycosylation sites exposed a neutralization epitope N-terminal to
the MPER [23]. From Yuste et al., we would predict that cleavage
of N-linked glycans at 611 616, 625 and/or 637 might also be
responsible for directly unmasking the 2F5 and 4E10 gp41
epitopes, or inducing conformational changes of the Env that
indirectly expose the gp41 membrane proximal external region, or
both. Indeed, three out of four glycosylation sites in gp41 were
occupied in recombinant untreated JRFL gp140, and were
removed in natively deglycosylated JRFL gp140 (Figure 7).
Additionally, we and others have previously shown that enhanced
exposure of the MPER epitope by single amino acid changes can
increase the binding and neutralizing activity by broadly
neutralizing MPER antibodies [46–48].
Since the 4E10 antibody is markedly polyreactive [6], it was
important to consider that the 4E10 epitope exposed on PNGase
F-treated Env gp140 might be distant from the 672WTDIT-
NWLWY681 gp41 4E10 nominal epitope. Hages-Braun et al. have
suggested that two ancillary 4E10 binding sites are located on
gp120 at 34 LWVTVYYGVPVWK46 and on gp41 at 512AVGI-
Figure 7. Glycan analysis of native partially deglycosylated JRFL gp140 protein. Native deglycosylation of JRFL gp140 protein was
performed using PNGase F (500 unit/mg protein) as described in the materials and methods. Amino acid sequence numbers were based on the HXB2
sequence. The signal peptide and variable regions of the sequence were identified above the sequence. See Table S1 for mass spectrometry analysis
data summaries.
doi:10.1371/journal.ppat.1002200.g007
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GAVFLGFLGAAGSTMGAASMTLTVQAR542 [38]. However,
our studies demonstrated no 4E10 binding to PNGase F-treated
gp120, and PNGase F-treated gp140, but not gp120, absorbed the
binding of mAb 4E10 to the gp41 peptide (P-4E10,
SLWNWFNITNWLWYIK). These data suggested that the reason
that mAbs 2F5 and 4E10 RUAs can bind PNGase-treated JRFL
gp140 is most likely due to enhanced exposure via glycan
unmasking of the gp41 MPER, or an induced gp41 MPER
conformational change that allowed for a faster on-rate for mAbs
2F5 and 4E10 to bind to gp41. That most of the deglycosylated
forms of JRFL and CON-S gp140 are oligomeric and only a
minor species is monomeric for both Envs (Figure S1),
demonstrates that the exposure of the MPER is on oligomeric
Env forms.
A number of studies have suggested that deglycosylation can
affect HIV-1 envelope antigenicity and immunogenicity
[17,19,21–23,49–54]. A non-glycosylated outer domain of gp120
has been reported to be immunogenic and induce weak
neutralizing antibodies in rabbits [50]. For example, loss of sialic
acids on gp120 has been reported to improve Env immunogenicity
[49,55]. Strategies for native deglycosylation of Env have been
described that can improve both immunogenicity and sensitivity of
resulting virions to neutralization [51,53].
Frey et al. have reported weak or no binding of recombinant
HIV-1 Envs to mAbs 2F5 and 4E10, but strong binding of these
antibodies to a stabilized gp41 intermediate molecule [15].
Whether the epitope on natively deglycosylated recombinant
JRFL gp140 is in the intermediate conformation of gp41 seen by
mAbs 2F5 and 4E10 during the infection process is not known.
However, we have recently shown that glycosylated JRFL gp140
Env can prime for an MPER peptide-liposome boost and induce
antibodies focused on the DKW core 2F5 epitope that bind to the
gp41 intermediate epitope (Sekaran, M. Alam, SM, Haynes, BF,
unpublished). That deglycosylated JRFL gp140 is more immuno-
genic in rhesus macaques than glycosylated JRFL for 2F5 epitope
MPER antibodies suggests that deglycosylated JRFL may have
enhanced immunogenicity as a prime in this prime-boost setting.
Other factors in addition to the conformation of the MPER
neutralizing epitopes appear to contribute to regulation of anti-
MPER broad neutralizing antibodies. For example, we now have
experimental data with mAbs 2F5 and 4E10 knock-in mice that B
cells expressing these VHs are controlled by both central and
peripheral tolerance mechanisms in these animals [13,14]. Thus,
immunogen design for optimal neutralizing epitope exposure is
only one-component of the problem for inducing anti-MPER
antibodies. Nonetheless, the increased affinity of the non-
denaturing PNGase F-treated gp140 Env may render it a
preferred Env immunogen in the setting of formulation of Envs
with potent adjuvants that are designed to circumvent peripheral
tolerance [56,57].
While the RUAs in this paper are close approximations of the
unmutated ancestor B cell receptors on naı̈ve B cells, it should be
noted that they are only inferred and may not precisely mimic the
binding of membrane bound IgM B cell receptors on naı̈ve B cells.
Our data demonstrate that RUAs of both mAbs 2F5 and 4E10 can
recognize the MPER well in the context of natively deglycosylated
JRFL gp140, but not in fully glycosylated JRFL gp140.
Interestingly, the glycosylated group M consensus Env CON-S
gp140 constitutively bound to both 2F5 RUAs. This finding is
consistent with our previously published site-specific glycan
analysis of the CON-S gp140 in which we found, unlike JRFL
gp140, that CON-S gp140 when expressed in 293T cells, has no
occupied gp41 glycan sites [34]. That native deglycosylation of
CON-S gp140 still resulted in enhanced binding to unmutated
ancestors of 2F5 and 4E10 suggests that removal of gp120 glycans
modulates access to gp41 as well. Thus, the inability of mAbs 2F5
and 4E10 reverted unmutated ancestors to react with recombinant
HIV-1 gp140 Envs in some instances may be due to glycan
masking or glycan modulation of conformations of MPER
neutralizing epitopes, or may be due to ‘‘holes’’ in the native B
Figure 8. Model of glycosylation patterns of recombinant WT JRFL gp140 and partially deglycosylated gp140 under non-
denaturing conditions. Shown are the images that were modeled based on the cryo-electron tomography as described by Schief [60]. Panel A:
HIV-1 recombinant JRFL Env exhibits a number of high mannose glycans as determined by mass spectrometry (Figure 7 and Table S1). In this figure,
the gp120 bearing the V3 loop [61] (PDB 2B4C)] trimer (red) is modeled over the cryo-EM structure (white mesh) (36), and its representative glycans
are indicated in blue with those that are bound by the antibody 2G12 [37] in white. The fold of the prefusion gp41 trimer is not known, so gp41
glycans (yellow) have been positioned approximately equidistant around the stalk. Glycans bound to gp120 residues in the V1 and V2 loops have
similarly been placed in reasonable locations across the top of the trimer. Depicted in Panel B are the glycans remaining after treatment with PNGase-
F. In general, PNGase is able to remove the glycans that are attached to flexible parts of the gp120 structure, presumably allowing the enzyme to gain
access to recognition elements and cleavage points. Glycans attached to Asn residues occuring in relatively stable structural elements of gp120
persist after PNGase-F treatment.
doi:10.1371/journal.ppat.1002200.g008
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cell repertoire for glycosylated HIV-1 Env. That the MPER 2F5
and 4E10 gp41 epitopes can be exposed with native deglycosyla-
tion, to us suggests the importance of glycan masking on
glycosylated gp140 to 2F5 and 4E10 unmutated ancestor antibody
non-reactivity. In light of the host immunoregulatory controls that
also appear to play roles in control of MPER broad neutralizing
antibody induction, both structural considerations of immunogen
design targeted to optimized binding to reverted unmutated
ancestor antibodies, in concert with methods of immunogen
formulation to access and drive MPER-specific naı̈ve and memory
B cell proliferation likely will be required for the ultimate safe
induction of MPER broad neutralizing antibodies.
Materials and Methods
Cloning and Expression of HIV-1 Env Proteins
A codon-optimized gene encoding the gp140CF (C = gp120-
gp41 cleavage site deleted, F = fusion domain-deleted) of HIV-1
WT JRF Env in plasmid pR-JRFL140 (kindly provided by Feng
Gao, M.D., Duke, Durham, North Carolina) was subcloned to
pcDNA3.1(-)/Hygro eukaryotic expression vector (Invitrogen,
Carlsbad, CA) via Xba I site at the 59 end and a BamHI site at the
39 end under the regulation of the CMV immediate early promoter.
The resulting recombinant plasmid, pcDNA/H-JRFL 140, was
linearized by restriction endonuclease Ssp I (Invitrogen, Carlsbad,
CA) digestion. Two mg of purified plasmid was transfected into
HEK293T cells (ATCC, Bethesda, MD) at approximately 80%
confluence with LipoFectamine 2000 (Invitrogen, Carlsbad, CA)
per the manufacturer’s protocol. Two days post transfection, cells
were digested with trypsin-EDTA, resuspended with DMEM HG
media (Sigma, St. Louis, MO) containing 20% fetal bovine serum
(DMEM-20) and 200 mg/mL of hygromycin B (Sigma) (selection
media), and dispersed to 10–20 100 mm polystyrene Petri dishes
(Becton-Dickinson, Franklin Lakes, NJ). Hygromycin B-resistant
colonies were picked, digested and re-suspended in selection media.
Stably transfected cells were cloned by limiting dilution and adapted
in serum-free media Pro293A (BioWhittaker, Switzerland), and
used for production of purified recombinant WT JRFL gp140
protein using lectin agarose beads (Galanthus Nivalis, Vector
Laboratories, Burlingame, CA) and stored at 280uC until use
[29]. The group M consensus gp140 Env, CON-S gp140 CFI (C =
gp120-gp41 cleavage site deleted, F = fusion domain-deleted, I =
Figure 9. SPR measurements of binding of inferred RUAs of 2F5 and 4E10 to WT glycosylated and natively deglycosylated JRFL
gp140 Env proteins. A dose range (from 20–100 mg/mL as indicated) of RUA1 (A–B) and RUA2 (C–D) inferred from the mutated 2F5 antibody
sequence and one RUA (4E10 RUA, 20–80 mg/mL) (E–F) inferred from the 4E10 mutated antibody sequence were tested by SPR for binding to WT
glycosylated (WT) and maximally deglycosylated (Deg) JRFL gp140 Env proteins immobilized on adjacent flow cells of the same sensor chip. Each
antibody was captured on an anti-Ig Fc immobilized chip as described [7]. Neither of the RUAs of 2F5 (Panels 9A–9C) nor 4E10 (Panel 9E) bound to WT
glycosylated JRFL gp140 Env protein, while reactivity of the RUAs of 2F5 (Panels 9B–9D) and 4E10 (Panel 9F) to deglycosylated JRFL gp140 Env
proteins was present with the Kds and rate constants shown in each panel. Rate constants were derived by curve fitting analysis and using a 1:1
Langmuir model.
doi:10.1371/journal.ppat.1002200.g009
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immunodominant gp41 region deleted) protein was expressed and
produced as previously described [29].
Cells and Viruses
DC-SIGN-expressing NIH 3T3 cells, parent NIH 3T3 cells,
TZM-BL cells that express CD4/CCR5/CXCR4 were obtained
from NAID/NIH AIDS Reagent Repository. Cell lines were
grown in Dulbecco’s modified Eagle’s medium (DMEM, Life
Technologies/Invitrogen) supplemented with 10% heat-inactivat-
ed fetal bovine serum (FBS).
Monoclonal Antibodies (mAbs) and Soluble CD4 (sCD4)
Human
MAbs known to bind epitopes on gp120 (A32) [31] the gp120
V3 loop (F39F), and the CCR5 binding site (17b) [30], were kindly
provided by James Robinson (Tulane Medical School, New
Orleans, LA). Anti-gp41 membrane proximal external region
(MPER) mAbs 2F5, and 4E10, and 2G12 [33] were purchased
from Polymun Scientific, Vienna, Austria. T8 is a murine mAb
that binds to the gp120 C1 region (a gift from P. Earl, NIH).
Mouse mAb 3B3 binds near the N-terminus of gp120 and has
broadly cross reactivity with HIV-1 gp120 proteins of different
subtypes [32]. Mouse anti-DC-SIGN monoclonal antibodies [58]
and recombinant sCD4 were obtained from the NIAID.NIH
AIDS Reagent Repository. MAb 1b12 against the CD4BS was the
gift of Dennis Burton, Scripps, La Jolla, CA [20].
Deglycosylation of Proteins
Peptide-N-glycosidase F (PNGase F) that removes N-linked
carbohydrates was purchased from New England Biolabs (Beverly,
MA). Progressive native deglycosylation was performed using
100 mg of HIV-1 JRFL Env protein with varied amounts of
PNGase F ranging from 5, 10, 20, 50, 100 and 500 units (U) per
mg of HIV-1 JRFL gp140 Env protein. For each experiment,
100 mg of Env protein were digested with indicated amount of
PNGase F in 200 mL of volume (resulting in the protein
concentration of 0.5 mg/mL). The reaction was carried out at
37uC for 24 h and then stopped by freezing the reaction mixtures
at 280uC. Deglycosylation in denaturing conditions was per-
formed by digesting every 100 mg of pre-denatured protein in
denaturing buffer (0.5% SDS and 1.0% b-ME) at 100uC for
10 min with 1 mL (500 U) of PNGase F at 37uC for 2 h using the
protocol as recommended by the manufacturer. Deglycosylation of
the JRFL Env protein under the native condition was optimized
by either prolonging the incubation time or increasing the amount
of enzyme used in order to achieve the maximal deglycosylation.
In the former case, the incubation time extended up to 7 days only
minimally improved the extent of native deglycosylation of gp140
(data not shown). On the other hand, the prolonged incubation
increased the risks for protein to be degraded. In contrast, with the
fixed reaction time (approximately 24 h), the increased amounts of
the enzyme dramatically increased the completeness of the native
deglycosylation of Env. Deglycosylation under non-denaturing
Figure 10. Enhanced immunogenicity of deglycosylated JRFL gp140 Env as determined by plasma levels of 2F5 epitope binding
antibodies in immunized rhesus macaques. Rhesus macaques (4 per group) were immunized at weeks 0 (prime) and 4 (boost) with 100 ug of
either glycosylated (WT) or natively deglycosylated (Deg) JRFL gp140 Env. Plasma samples were collected at weeks 2 and 6 from each group (as
indicated on the top of the panels) and were assessed for binding to WT JRFL gp140 Env and Deg JRFL gp140 Env (Panel 10A). The antibody
responses to wild-type JRFL Env or to Deg JRFL Env were undetectable after the prime and are not shown. The responses to WT JRFL Env and Deg
JRFL Env after the week 4 boost (the week 6 blood draws) are shown. The antibody response to 2F5 nominal MPER peptide
(QQEKNEQELLELDKWASLWN) after the prime (week 2) and boost (week 6) is shown (Panel 10B). Shown on the x axis are the reciprocal dilutions
of plasma of the immunized moneys used in ELISA. The dotted lines indicate the negative cut-off values. The level of 2F5 epitope antibody response
at the initial dilution (1:25) in week 6 plasma were higher in animals immunized with deglycosylated JRFL Env than in animals immunized with WT
JRFL Env (p = 0.035, Student’s t test). Data shown are mean values +/2 standard deviation derived from 3 separate experiments performed.
doi:10.1371/journal.ppat.1002200.g010
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conditions with PNGase F (500 U per mg of JRFL Env) reduced
the size of the deglycosylated JRFL gp140 Env protein close to the
theoretical polypeptide size (approximately 80 kDa) as analyzed by
SDS-polyacrylamide gel electrophoresis (SDS-PAGE), which
indicated that approximately 80% of carbohydrates have been
removed. Deglycosylation of CON-S gp140CFI was performed
under non-denaturing conditions using PNGase F at 500 U per mg
of Env protein.
SDS-PAGE and Western Blot Analysis of the Env Proteins
Untreated and deglycosylated HIV-1 JRFL gp140CF and
CON-S gp140CFI Env proteins were fractionated on 4–12%
Bis-Tris SDA-PAGE gels (Invitrogen, Carlsbad, CA) under
reducing (4% Beta-mercaptoethanol, b-ME, Fisher Scientific, Fair
Lawn, NJ) or non-reducing conditions, stained with coomassie
blue dye, or transferred onto nitrocellulose filters and probed with
anti-Env human mAbs 17b, 1b12, 2F5, 2G12, 4E10, A32, F39F.
Goat anti-human IgG alkaline phosphatase (AP) conjugates
(Sigma Aldrich, Inc, St. Louis, MO; 1:3,000 dilution) was used
as secondary antibodies in Western-blots.
Surface Plasmon Resonance (SPR)
SPR assays using a BIAcore 3000 instrument were carried out
to characterize the binding of untreated and deglycosylated HIV-1
Env proteins to anti-HIV-1 MPER mAbs 2F5 and 4E10 as well as
to their inferred reverted unmutated ancestors. Data analysis was
performed with BIAevaluation 3.0 software (BIAcore Inc,
Upsaala, Sweden). To measure the affinity (Kd) and kinetics of
the interaction of the Env proteins with mAbs, the Env
glycoproteins at varying concentrations were flowed over mAb
2F5 or 4E10 that were captured on anti-Fc IgG immobilized on
the sensor chip CM5 with amine coupling kit (Biacore AB) and as
described earlier (7, 8, 59). The binding data were recorded in real
time at 25uC with a continuous flow of phosphate-buffered saline
(150 mM NaCl, 0.005% surfactant P20 [pH 7.4]) at 30 mL/min
following subtraction of non-specific signal over the control mAb
surface [7,8,59].
ELISA
EIA plates (Costar 3590, Corning, NY) were coated with JRFL
gp140 protein (0.2 mg/well) in 100 mL of carbonate-bicarbonate
(CBC) buffer (pH 9.6) over night at 4uC. Plates were then blocked
with CBC containing 3% BSA (Sigma, St. Louis, MO) for 2 h at
room temperature (RT). To evaluate the antibody binding
kinetics, serial dilutions of each mAb (17B, 1b12, 2F5, 2G12,
4E10, and F39F) starting from 10 mg/ml in 50 mL in dilution
buffer (PBS, 0.05% Tween-20, 2% goat serum and 3% BSA) were
added to the plate followed by the incubation at RT for 1 h. After
washing with dilution buffer, goat anti-human IgG-AP (Sigma, St.
Louis, MO) was added and incubated in the same way to detect
the binding of human antibodies to Env proteins. Alternatively,
equal volume of native deglycosylation and mock deglycosylation
reaction solutions containing equal amount of initial Env protein
were serially diluted in CBC buffer (pH 9.6) starting from 10 mg/
mL (2-fold serial dilution for 12 point titrations). One hundred
(100) ml of the diluted solution were coated on the 96-well EIA
plate (Costar 3590, Corning, NY) each well and incubated at 4uC
overnight and then blocked with CBC containing 3% BSA (Sigma,
St. Louis, MO) for 2 h at RT.
Each human mAb was diluted in buffer (PBS, 0.05% Tween-20,
2% goat serum and 3% BSA) to 1.0 mg/mL and 100 ml per well of
each diluted antibody was incubated at RT for 1 h. For sCD4,
100 ml of 0.2 mg/mL was used. Goat anti-human IgG-AP (Sigma)
was used to detect the binding of human antibodies to Env
proteins. For detection of binding of sCD4, biotin-labeled anti-
CD4 mAb (0.1 mg/mL in 100 ml/well) and the Strepavidin
(Promega, 1:1000, 100 ml/well) were used. In selected experi-
ments, Env oligomers were captured on plates pre-coated with
mAb 3B3 and then tested for mAb reactivity as above. ELISA
results were read at 405 nm using ELISA radar (Bio-Rad,
Berkeley, California).
Rhesus macaque binding antibodies to HIV-1 WT glycosylated
JRFL gp140 Env and deglycosylated JRFL gp140 Env were
assayed by indirect ELISA. HIV-1 WT glycosylated JRFL gp140
Env and deglycosylated (Deg) JRFL gp140 Env, 2F5 nominal
MPER epitope peptide SF62 (QQEKNEQELLELDKWASLWN)
and 4E10 eiptope peptide P-4E10 (SLWNWFNITNWLWYIK)
were coated at 200 ng/well in 96-well ELISA plates (4 degrees C)
followed by incubation with dilutions of immune plasma. AP
conjugated goat anti-monkey IgG heavy- and light chain specific
antibody was used as seconday antibody.
DC-SIGN Binding Assay
To assess the reactivity of untreated and deglycosylated proteins
to bind DC-SIGN, WT glycosylated and deglycosylated JRFL
gp140 proteins were chemically labeled with the Alexa Fluor 647
dye (AF647) using a protocol as recommended by the manufac-
turer (Invitrogen, Carlsbad, CA). NIH 3T3/DC-SIGN or the
parent NIH 3T3 cells (56105 cells in 100 mL of PBS containing
1% BSA in the presence of 1 mM Ca++ and Mg++ ions) were
incubated with 1.0 mg/mL of the AF647-labeled undeglycosylated
or deglycosylated JRFL gp140 proteins at 4uC for 30 min. The
cells were washed for 4 times with the PBS buffer. The cells were
resuspended in 400 100 mL of PBS buffer and analyzed with an
LSRII flow cytometer (Becton Dickinson) [58]. CD4 expressing
TZM-b1 cells were used as a positive control for binding of the
AF647-labeled undeglycosylated and deglycosylated JRFL gp140
proteins.
Analysis of Carbohydrates by Mass Spectrometry
We have previously analyzed and compared JRFL gp140CF
and CON-S gp140CFI Envs for glycan site-occupation and
content [34]. To determine the glycosylation profile of both native
and the deglycosylated JRFL gp140 Env proteins, the latter were
treated with proteases and the digestion products were analyzed by
LC/MS, as described previously and below [34,35].
Deglycosylated JRFL gp140 Env envelope proteins were either
treated with Endo H or (separately) Endo F3, to reduce the glycan
heterogeneity to a single N-acetlyhexosamine, attached to the
glycosylation site. Core fucosylated residues also remained
fucosylated in this procedure. Typical conditions included
incubating the Env (approximately 7 fmol) with enzyme, at a
ratio of at least 30 U/mg of Env protein. For Endo H
deglycosylation experiment, the sample was denatured with 2 M
urea in 100 mM tris buffer (pH 5.5) followed by the addition of
2 mL of Endo H. After thorough mixing, the reaction was
incubated for 48 hours at 37uC. For Endo F3 deglycosylation
experiment, samples were incubated with 6 mL of 250 mM
NH4C2H2O2 (pH 4.5) and 2 mL of Endo F3 for two weeks at
37uC.
After deglycosylation, proteins were split into two fractions and
subjected to enzymatic digestion using trypsin and Glu-C. Prior to
enzyme addition, proteins were unfolded using 6 M urea, and
reduced and alkylated at room temperature using 10 mM DTT
and 15 mM IAA at RT, respectively. Digestion conditions were
carried out in tris buffer with 3 mM EDTA overnight at 37uC. For
tryptic digest, pH was 8.5 and protein to enzyme ratio was 30:1;
for Glu-C digest, pH was 7.8 and the protein to enzyme ratio was
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20:1. Both reactions were quenched with the addition of 1 mL
glacial acetic acid. The digestion protocols were performed three
times on different days, with the same initial batch of protein, to
ensure reproducibility and reliability. As an additional control
experiment, WT glycosylated protein was subjected to the same
protocols to verify that the method would effectively detect all sites
on the protein that remained glycosylated.
For carbohydrate analysis, peptides were detected by LC-MS,
using a Dionex UltiMate capillary LC system (Sunnyvale, CA)
equipped with a FAMOS well plate autosampler; adjoined to a
Fourier transform ion cyclotron resonance mass spectrometer
(LTQ-FT, ThermoScientific, San Jose, CA). Separation of the
sample (5 mL) was achieved using a C18 PepMap 300 column
(300 mm i.d. 615 cm, 300 Å, LC Packings, Sunnyvale, CA) at a
flow rate of 5 mL/minute. Separation was achieved using a linear
gradient over 65 minutes, and the eluted peptides were ionized
using a 2.8 kV source voltage for ESI. High resolution MS and
low resolution MS/MS data were collected using a data-
dependent scanning protocol, where the five most intense ions
were selected for MS/MS, after each high resolution MS run, and
those ions were subsequently dynamically added to an exclusion
list for 3 minutes. Peptides (both deglycosylated, and those with
remaining glycosylation) were detected using the MS and MS/MS
data with the assistance of a Mascot search (Matrix Science,
London, UK, version 2.2.04), after inputting a custom HIV Env
database. All automated assignments were further verified by
manually assigning the relevant MS/MS spectra. All glycosylation
sites were detected as glycosylated or deglycosylated, except for
N406, which was not detected by MS analysis.
Ethics Statement
This study involved in the use of rhesus macaques was carried
out in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National
Institutes of Health in BIOQUAL (Rockville, MD.) BIOQUAL is
fully accredited by AAALAC and through OLAW, assurance
number A-3086. The protocol was approved by the BIOQUAL
IACUC. All physical procedures associated with this work were
done under anesthesia to minimize pain and distress. Four rhesus
macaques per group were immunized intramuscularly with
100 ug/dose of HIV-1 JRFLgp140 Env wild-type (WT) or JRFL
gp140 CF Env deglycosylated using PNGase F at 500 U/mg Env
using AS01B adjuvant (generously provided by Gerald Voss,
GlaxoSmithKline Biological, Rixensart, Belgium) at week 0 and 4.
Blood samples were collected at week 2 and week 6 for isolation of
immune plasma.
Supporting Information
Figure S1 Analysis of deglycosylated JRFL protein in
blue native (BN) gel and SDS-PAGE. JRFL and CON-S
gp140 Env and JRFL gp140 and the CON-S gp140 Env proteins
that were natively deglycosylated using 500U PNGase F/ug Env
were fractionated in either blue native gel (Panel S1A) or in 4-12%
SDS-PAGE under reducing condition and stained with coom-
massie blue (Panel S1B). The + and – above the individual lanes
indicate that JRFL gp140 or CON-S gp140 were treated (+) or not
treated (-) with 500U PNGase F/mg Env. In BN-PAGE gel
analysis, deglycosylated JRFL gp140 and CON-S gp140 Envs
migrated as monomer, dimer and trimer with decreased molecular
weight as results from the removal of glycans compared with the
WT glycosylated Envs (panel S1A). Panel B shows that in SDS-
PAGE under reducing conditions, treatment with 500U/ug Env
PNGase F reduced the molecular weight to approximately 80 kDa
for JRFL gp140 CF Env and 75kDa for CON-S gp140 CFI Env.
The slightly lower molecular weights of protein bands of CON-S
gp140 were due to the deletion of the immunodominant region in
the CON-S gp140CFI design compared with JRFL gp140CF
protein without deletion of the immunodominant region [29].
Note that in the reduced Coomasie stained SDS-PAGE gels (Panel
S1B) there are no bands higher than gp140, indicating compete
reduction of the Env dimers and higher MW forms.
(TIF)
Figure S2 Binding of mAbs 2F5 and 4E10 to deglycosy-
lated Env gp120 proteins. Shown is the evidence of lack of
binding in ELISA of mAbs 2F5 and 4E10 to Env gp120 proteins
directly coated on ELISA plates after progressive deglycosylation
from 0 to 500 U per mg of Env protein (DEG 0-DEG 500). Binding
of sCD4 to Env gp120 in this assay setting was maintained on Env
gp120 protein up to 100 U of PNGase F.
(TIF)
Figure S3 Inhibition of binding of mAb 4E10 to 4E10
binding epitope peptide (P4E10) by WT glycosylated and
deglycosylated JRFL 140 protein. MAb 4E10 at 50 mg/ml
was first pre-incubated with the indicated concentrations (in x-axis)
of HIV-1 Env protein of either WT glycosylated (Deg 0) or
moderately deglycosylated (Deg 20, 20 U per mg of protein) JRFL
gp140CF or Env gp120, and then assayed for binding to a 4E10
epitope peptide (SLWNWFNITNWLWYIK) by ELISA. Incuba-
tion of either WT (Deg 0) or moderately deglycosylated (Deg 20)
Env gp120 had little effect on the binding of mAb 4E10 to the
4E10 epitope peptide, while deglycosylated JRFL gp140 protein
showed more efficient absorption than did WT glycosylated JRFL
Env protein of the binding of mAb 4E10 to the 4E10 epitope
peptide.
(TIF)
Figure S4 Inhibition of mAb 4E10 binding to deglycosy-
lated JRFL gp140 proteins. MAb 4E10 was pre-incubated
with indicated concentrations (x-axis) of 4E10 epitope peptide
(SLWNWFNITNWLWYIK) and then assayed in ELISA for
binding to deglycosylated (500 U PNGase F) JRFL gp140 Env
protein. Percentage of binding (y axis) of absorbed mAb 4E10 to
the Env antigen was determined in comparison with the binding of
non-absorbed antibody and plotted versus the amount of 4E10
peptide used for absorption. 4E10 peptide (SLWNWFNITNWL-
WYIK) inhibited the binding of 4E10 mAb to deglycosylated
JRFL gp140 in a dose-dependent manner. Data shown are
representative of three experiments performed.
(TIF)
Figure S5 Binding of soluble (s) CD4 to WT glycosylated
and deglycosylated CON-S gp140 by SPR. Surface plasmon
resonance assays were performed as described in Materials and
Methods. Shown are the binding of sCD4 to the WT glycosylated
(WT) (Panel S5A) and deglycosylated (Deg) (Panel S5B). sCD4 was
covalently immobilized to a CM5 sensor chip (BIAcore), and WT
glycosylated and deglycosylated CON-S gp140 injected over each
surface (5-20ug/mL and 40-100 mg/mL, respectively). Rate
constants and Kd measurements were made using the 1:1
Langmuir model. The on-rate (Kon), off -rate (Koff) and Kd are
indicated in the individual panels. Each analysis was performed at
least twice.
(TIF)
Figure S6 Analysis of antigenic epitopes expressed on
WT glycosylated and deglycosylated CON-S gp140 by
surface plasmon resonance (SPR). SPR assays were
performed as described in Materials and Methods. Shown is the
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ability of WT glycosylated and deglycosylated CON-S gp140 to
bind to mAb 17B (Panel S6B). sCD4 or HIV-1 mAbs T8 and A32
were covalently immobilized to a CM5 sensor chip (BIAcore), and
WT glycosylated and deglycosylated CON-S gp140 were injected
over each surface to capture 320 – 500 RU of Env proteins. To
determine induction of 17b MAb binding to glycosylated and
deglycosylated CON-S gp140, Env proteins at equivalent RU
amounts were captured on individual flow cells immobilized with
sCD4 or mAb A32 or T8. Following stabilization of each of the
surfaces, varying concentrations of mAb 17b (25 to 100ug/ml) was
injected and allowed to flow over each of the immobilized flow
cells as illustrated in the diagram above the SPR profiles in Panel
B. The on-rate (kon), off -rate (koff) and Kd are indicated in
individual panels. Each analysis was performed at least twice.
(TIF)
Figure S7 SPR assays of binding of mAbs 4E10 and 2F5
to WT glycosylated and deglycosylated CON-S gp140
Envs. MAbs 2F5 (Panels S7A, S7B) and 4E10 (Panel S7C, S7D)
were bound to anti-human Ig Fc immobilized on the CM5 sensor
chip. Then varying concentrations (ranging from 20 to 100 mg/ml)
of glycosylated (WT) or deglycosylated (Deg) Con S gp140 (20-
100 mg/ml or 1 to 40 ug/mL as indicated) proteins were injected
over the mAbs on the chip and binding kinetics were recorded.
Rate constants and Kd measurements were made using the 1:1
Langmuir model and data are as indicated. Deglycosylation of
CON-S gp140 enhanced 2F5 and 4E10 Kds by ,4 fold and ,7-
fold, respectively. Each analysis was performed at least twice.
(TIF)
Figure S8 SPR measurements of binding of inferred
RUAs of 2F5 (S8A-S8D) and 4E10 (S8E and S8F) to WT
glycosylated and deglycosylated CON-S gp140 Envs. Dose
ranges (20-100 mg as indicated) of RUA1 (Panels S8A and S8B)
and RUA2 (Panels S8C and S8D) inferred from mAb 2F5, and
one RUA (Panels S8E and S8F) inferred from mAb 4E10 were
tested by SPR for binding to glycosylated (WT) and deglycosylated
(Deg). Each antibody was captured on an anti-Ig Fc immobilized
chip as described earlier [7,8,59]. Rate constants and Kd
measurements were made using the 1:1 Langmuir model. The
on-rate (Kon), off -rate (Koff) and Kd are indicated in individual
panels. Each analysis was performed at least twice.
(TIF)
Table S1 Mass spectrometry analysis of deglycosylated
JRFL gp140 Env treated with Endo H and Endo F3.
(DOC)
Table S2 Variable region sequence of mAb 2F5 and
4E10 as well as their inferred reverted and unmutated
heavy- and light-chain genes. Shown is the summary of MS
data. Each peptide containing a potential glycosylation site was
detected as either a glycopeptide, a deglycosylated peptide, or as a
nativly nonglycosylated speices. Original regions of HIV-1 Env for
the detected individual peptides are indicated.
(DOC)
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